Unternehmensübersicht
Horizon Technology Finance Corporation operates as a business development company with a primary focus on providing secured debt and venture lending investments to venture capital-backed enterprises within the technology, life science, and healthcare information sectors. Although the specific sector and industry classifications are not explicitly defined in the available data, the company's operational model targets development-stage investments, positioning it as a specialized financial intermediary for high-growth private enterprises. The firm reports an annual revenue of $108.44M and carries a market capitalization that is not currently disclosed in the provided facts, while the employee count remains unlisted. The magnitude of its $108.44M revenue stream indicates a significant scale within the niche of specialized lending, suggesting the entity has established substantial operational capacity to manage a portfolio of development-stage assets without the public disclosure of a market cap figure.
Finanzielle Gesundheit
The company generated revenue of $108.44M over the trailing twelve months, yet it recorded a net income of $-2,505,000, revealing a cost structure where expenses and provisions significantly outweigh the top-line earnings. The absence of disclosed EBITDA figures limits the direct assessment of operational cash generation before interest and taxes, but the net loss highlights a specific phase of capital deployment or high interest costs common in venture lending models. Despite the negative net income, the entity produced free cash flow of $34.32M, which signifies strong operational liquidity and financial flexibility to fund new investments or service obligations without relying on external equity financing. The gross margin stands at 100.0%, indicating a business model where costs of goods sold are negligible relative to revenue, typical of financial intermediaries, while the operating margin of 84.6% reflects highly efficient management of core lending operations. However, the profit margin is -2.3%, confirming that non-operating expenses or interest costs are eroding bottom-line profitability. The balance sheet shows a cash position of $34.82M against total debt of $435.50M, resulting in a debt-to-equity ratio of 125.66, which characterizes the firm as highly leveraged to maximize returns on invested capital. The current ratio of 3.41 indicates a robust short-term liquidity position, suggesting the company holds sufficient current assets to cover its current liabilities with a significant buffer. Return on equity is reported at -0.8%, reflecting the dilution of shareholder value due to the net loss, whereas return on assets is 7.2%, demonstrating that the asset base is generating positive economic returns before financing costs.
Bewertungsanalyse
The trailing twelve-month price-to-earnings ratio is 21.01, while the forward P/E ratio is not disclosed, implying that market expectations for near-term earnings growth are either volatile or currently negative given the recent net loss. The price-to-book ratio is 2.47, suggesting that the market values the company at a significant premium over its tangible book value, likely reflecting the high quality of its loan portfolio and growth potential. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are not available in the current dataset, preventing a direct comparison of revenue-based or enterprise value multiples against peers. The stock has traded within a 52-week range between a high of $26.61 and a low of $24.60, and without a specific current price, the trading position relative to this range cannot be calculated, though the narrow spread suggests relative price stability. The beta of 1.17 indicates that the stock exhibits higher volatility than the broader market, meaning price movements are likely to be amplified relative to general market fluctuations.
Growth & Income
Revenue growth year-over-year is 25.3%, demonstrating a robust expansion in the top line, while earnings growth is not applicable due to the reported net loss in the trailing twelve months. The absence of a dividend yield and payout ratio confirms that the company does not distribute dividends to shareholders, a strategy consistent with business development companies reinvesting all earnings into new lending opportunities and portfolio expansion. Instead of paying out income, the firm channels its free cash flow of $34.32M back into the business to acquire new assets and support the growth of its technology and life science portfolio. The overall growth profile is defined by rapid revenue expansion and a leveraged balance sheet designed to capitalize on high-growth opportunities, while the income profile relies entirely on future profitability rather than current cash distributions.